Metadon (Methadone Hydrochloride)

Methadone works by binding to mu‑opioid receptors in the brain and spinal cord, acting as a full agonist. This activation reduces the perception of pain and diminishes cravings and withdrawal symptoms in people with opioid use disorder, while its long half‑life maintains steady drug levels.

The appropriate dose of Metadon is individualized and must be determined by a qualified prescriber based on the patient’s clinical condition, prior opioid exposure, and response to therapy. Dosage adjustments are made under medical supervision to achieve optimal therapeutic effect while minimizing adverse reactions.

Safety of methadone during pregnancy and lactation should be evaluated by the treating physician. While methadone is sometimes used in pregnancy to reduce illicit opioid use, potential risks to the fetus and infant exist, and a risk‑benefit assessment is essential before continuation.

To place an order, submit an enquiry on the Metadon product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with shorter‑acting opioids such as morphine, methadone has a longer half‑life, allowing once‑daily dosing for maintenance therapy. It also possesses NMDA‑receptor antagonism, which may reduce tolerance development. However, it requires careful cardiac monitoring due to QT‑prolongation risk, a consideration less prominent with some alternatives.

Metadon should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, and store it away from direct sunlight or heat sources to maintain potency and stability.

Metadon is administered orally, typically as a tablet. The exact dosing schedule and administration instructions are provided by the prescribing clinician, who may adjust the regimen based on therapeutic response and tolerability.

The most serious risks include respiratory depression, especially when combined with other central nervous system depressants, and cardiac arrhythmias due to QT interval prolongation. Patients should be monitored for signs of severe sedation, breathing difficulties, or irregular heart rhythms.

Metadon is contraindicated in individuals with known hypersensitivity to methadone, those taking monoamine oxidase inhibitors, or patients with severe uncontrolled cardiac arrhythmias. Caution is also advised for patients with significant respiratory, hepatic, or renal impairment, and it should be avoided in unmonitored opioid‑naïve individuals.